Menu Close

Roundup: Men’s health-focused startup Bonatra buys femtech startup MyAva and more briefs

Bonatra expanding chronic disease management platform with MyAva acquisition

Bonatra, which is once focused on treating chronic health conditions in men, is expanding its platform to deal with women’s health and wellness through its latest acquisition of MyAva.

Founded in 2019, the femtech startup provides curated programmes and personalised plans to help women manage their chronic conditions, including PCOS and thyroid disorders.

“Acquiring MyAva enables us to expand our reach and deepen our expertise in women’s health, specifically for conditions like PCOS,” said Bonatra CEO and co-founder Rahul Kishore Singh. Bonatra offers personalised treatment plans based on IoMT-collected data to help men treat and manage their chronic conditions, such as hypertension and diabetes.

MyAva CEO and founder said they are elated to join Bonatra and “further the vision of making chronic care management accessible to all women” while strengthening their joint commitments to “making femtech more inclusive and integrated.”

Startoon gets US FDA clearance for wearable recovery tracking device

Indian medical device startup Startoon Labs has received the United States Food and Drug Administration’s 510(k) clearance for its flagship wearable health product.

Called Pheezee, the device measures the surface electromyogram of bulk muscles and the range of motion of primary joints to determine joint health. It is intended for use in tracking patients’ recovery from physiotherapy, neurological, and musculoskeletal injuries. 

Indian researchers use ML to detect CNS tumours

Researchers at the Indian Institute of Technology Madras have developed an ML-based computational tool to better detect cancer-causing tumours in the brain and spinal cord.

Available publicly online, the GBMDriver (GlioBlastoma Mutiforme Drivers) identifies driver mutations and passenger mutations in glioblastoma, which are key to developing therapeutic options for patients.

Ubie expands rare diseases partnership with Takeda 

Japanese health tech startup Ubie has expanded its digital transformation partnership with Takeda Pharmaceutical Co.

The expanded collaboration, according to a press statement, seeks to promote the early detection of rare diseases and gastrointestinal diseases. The two companies started their partnership in 2021 with the promotion of Ubie’s symptom checker and patient intake form.

Ubie also intends to introduce additional functions on top of its current offerings and to collaborate with Takeda on IT systems and data.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *